Búsqueda | Biblioteca Virtual en Salud Odontología. Uruguay

1.

Haemophilia prophylaxis: how can we justify the costs?

Feldman, B M; Berger, K; Bohn, R; Carcao, M; Fischer, K; Gringeri, A; Hoots, K; Mantovani, L; Willan, A R; Schramm, W.

Haemophilia ; 18(5): 680-4, 2012 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-22507524

2.

The optimal mode of delivery for the haemophilia carrier expecting an affected infant is caesarean delivery.

James, A H; Hoots, K.

Haemophilia ; 16(3): 420-4, 2010 May.

Artículo en Inglés | MEDLINE | ID: mdl-20028425

3.

Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project.

Kulkarni, R; Soucie, J M; Lusher, J; Presley, R; Shapiro, A; Gill, J; Manco-Johnson, M; Koerper, M; Mathew, P; Abshire, T; Dimichele, D; Hoots, K; Janco, R; Nugent, D; Geraghty, S; Evatt, B.

Haemophilia ; 15(6): 1281-90, 2009 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-19637999

4.

HLA and HIV-1: heterozygote advantage and B35-Cw04 disadvantage.

Carrington, M; Nelson, G W; Martin, M P; Kissner, T; Vlahov, D; Goedert, J J; Kaslow, R; Buchbinder, S; Hoots, K; O'Brien, S J.

Science ; 283(5408): 1748-52, 1999 Mar 12.

Artículo en Inglés | MEDLINE | ID: mdl-10073943

5.

Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study.

Smith, M W; Dean, M; Carrington, M; Winkler, C; Huttley, G A; Lomb, D A; Goedert, J J; O'Brien, T R; Jacobson, L P; Kaslow, R; Buchbinder, S; Vittinghoff, E; Vlahov, D; Hoots, K; Hilgartner, M W; O'Brien, S J.

Science ; 277(5328): 959-65, 1997 Aug 15.

Artículo en Inglés | MEDLINE | ID: mdl-9252328

6.

Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group.

Nicholson, A; Berger, K; Bohn, R; Carcao, M; Fischer, K; Gringeri, A; Hoots, K; Mantovani, L; Schramm, W; van Hout, B A; Willan, A R; Feldman, B M.

Haemophilia ; 14(1): 127-32, 2008 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-18005148

7.

A commentary on variant Creutzfeld-Jacob disease.

Hoots, K.

Haemophilia ; 16(2): 238-9, 2010 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-20487441

8.

Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group.

Abshire, T C; Brackmann, H H; Scharrer, I; Hoots, K; Gazengel, C; Powell, J S; Gorina, E; Kellermann, E; Vosburgh, E.

Thromb Haemost ; 83(6): 811-6, 2000 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-10896230

9.

The incidence and significance of hemostatic abnormalities in patients with head injuries.

Olson, J D; Kaufman, H H; Moake, J; O'Gorman, T W; Hoots, K; Wagner, K; Brown, C K; Gildenberg, P L.

Neurosurgery ; 24(6): 825-32, 1989 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-2747858

10.

Multilineage Immune-Mediated Cytopenias in Childhood: A Report of Five Patients.

Canpolat, C; Culbert, S; Zietz, H; Hoots, K.

Turk J Haematol ; 17(1): 13-22, 2000 Mar 05.

Artículo en Inglés | MEDLINE | ID: mdl-27265758

11.

'What wound did ever heal but by degrees?'.

Hoots, K.

J Thromb Haemost ; 5(8): 1575-6, 2007 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-17663727

12.

Saccharomyces cerevisiae infection in a patient with acquired immunodeficiency syndrome.

Doyle, M G; Pickering, L K; O'Brien, N; Hoots, K; Benson, J E.

Pediatr Infect Dis J ; 9(11): 850-1, 1990 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-2263436

13.

Comprehensive immune evaluation of seventy-eight hemophiliacs.

Kerman, R; Manner, C; Ford, K; Hoots, K.

Ann N Y Acad Sci ; 437: 540-3, 1984.

Artículo en Inglés | MEDLINE | ID: mdl-6242006

14.

Clotting factor concentrates and immune function in haemophilic patients.

Hoots, K; Canty, D.

Haemophilia ; 4(5): 704-13, 1998 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-9873875

15.

Human immunodeficiency and hepatitis virus infections and their associated conditions and treatments among people with haemophilia.

Goedert, J J; Brown, D L; Hoots, K; Sherman, K E.

Haemophilia ; 10 Suppl 4: 205-10, 2004 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-15479399

16.

Effects of plasma HIV RNA, CD4+ T lymphocytes, and the chemokine receptors CCR5 and CCR2b on HIV disease progression in hemophiliacs. Hemophilia Growth and Development Study.

Daar, E S; Lynn, H; Donfield, S; Gomperts, E; Hilgartner, M W; Hoots, K; Chernoff, D; Winkler, C; O'Brien, S J.

J Acquir Immune Defic Syndr ; 21(4): 317-25, 1999 Aug 01.

Artículo en Inglés | MEDLINE | ID: mdl-10428111

17.

Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS.

Gao, X; Nelson, G W; Karacki, P; Martin, M P; Phair, J; Kaslow, R; Goedert, J J; Buchbinder, S; Hoots, K; Vlahov, D; O'Brien, S J; Carrington, M.

N Engl J Med ; 344(22): 1668-75, 2001 May 31.

Artículo en Inglés | MEDLINE | ID: mdl-11386265

18.

Therapeutic choices for patients with hemophilia and high-titer inhibitors.

Kulkarni, R; Aledort, L M; Berntorp, E; Brackman, H H; Brown, D; Cohen, A R; Ewing, N P; Gringeri, A; Gruppo, R; Hoots, K; Leissenger, C; Peerlinck, K; Poon, M C; Wong, W Y.

Am J Hematol ; 67(4): 240-6, 2001 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-11443636

19.

Who should use recombinant factor VIII?

Hoots, K.

Ann Hematol ; 68 Suppl 3: S65-8, 1994.

Artículo en Inglés | MEDLINE | ID: mdl-8180258

20.

Mediastinal masses.

Mayhew, J F; Hoelzer, D J; Hoots, K.

J Pediatr ; 103(6): 1005, 1983 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-6644411

Biblioteca Virtual en Salud Odontología. Uruguay

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Haemophilia prophylaxis: how can we justify the costs?

The optimal mode of delivery for the haemophilia carrier expecting an affected infant is caesarean delivery.

Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project.

HLA and HIV-1: heterozygote advantage and B35-Cw04 disadvantage.

Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study.

Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group.

A commentary on variant Creutzfeld-Jacob disease.

Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group.

The incidence and significance of hemostatic abnormalities in patients with head injuries.

Multilineage Immune-Mediated Cytopenias in Childhood: A Report of Five Patients.

'What wound did ever heal but by degrees?'.

Saccharomyces cerevisiae infection in a patient with acquired immunodeficiency syndrome.

Comprehensive immune evaluation of seventy-eight hemophiliacs.

Clotting factor concentrates and immune function in haemophilic patients.

Human immunodeficiency and hepatitis virus infections and their associated conditions and treatments among people with haemophilia.

Effects of plasma HIV RNA, CD4+ T lymphocytes, and the chemokine receptors CCR5 and CCR2b on HIV disease progression in hemophiliacs. Hemophilia Growth and Development Study.

Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS.

Therapeutic choices for patients with hemophilia and high-titer inhibitors.

Who should use recombinant factor VIII?

Mediastinal masses.